NLS Acquisition

Veeva Systems has acquired Copli, focusing on agentic medical, legal, and regulatory (MLR) solutions for the life sciences industry.

Merck and Bio-Techne Corporation have entered into a definitive agreement pursuant to which Merck will, subject to customary closing conditions, acquire Bio-Techne for USD 73 per share in cash, representing a total enterprise value of approximately USD 11.3 billion, a 36% premium to Bio-Techne’s one-month volume weighted average trading price.

By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization, the company states.

Johnson & Johnson has announced it has entered into a definitive agreement to acquire Firefly Bio, biotech company advancing its Firelink degrader antibody conjugate (DAC) platform, for USD 1 billion in cash.

French pharma company Servier has entered into an agreement to acquire the muscular dystrophy business of US Edgewise Therapeutics for up to USD 2.65 billion, including upfront payment of USD 1.55 billion as well as up to USD1.1 billion in regulatory and commercial milestone payments.

The acquisition adds expertise and a next generation gene therapy platform to LEO Pharma’s pipeline through Replay’s high‑payload herpes simplex virus (HSV) delivery vector.